5 years ago

Safety of BTZ retreatment for patients with low-grade peripheral neuropathy during the initial treatment

Regina A. Swift, Jose Lutzky, Tanya M. Spektor, Shahrooz Eshaghian, Aleksandra P. Vidisheva, James R. Berenson, Joseph Z. Ye, Youram Nassir, Ronald G. Steis, Laura V. Stampleman, Mehdi M. Moezi, Imad A. Tabbara, Jacob D Bitran, James Wang, Sikander Ailawadhi, Kyle A Udd, Tina M Maluso



Neuropathy is an important complication that may limit treatment options for patients with multiple myeloma. Previous studies have focused on treatment efficacy and have shown that retreatment with bortezomib (BTZ) is an effective treatment option. The goal of this study was to focus on the clinical manifestations of peripheral neuropathy (PN) and to retrospectively compare the incidence and severity of PN between the initial BTZ regimen and upon retreatment. Furthermore, this study evaluated how certain factors affect BIPN, which will help determine what conditions should be considered prior to retreatment.


Charts were reviewed from 93 patients who were retreated with a BTZ-containing regimen after previously being treated with this drug.


Among the patients who developed PN, most patients in the study had low-grade neuropathy during the initial BTZ treatment (n = 52, 68%). The results showed no evidence of cumulative toxicity, and there was no significant difference in the incidence and severity of PN upon retreatment. Factors such as the presence of baseline PN, number of prior treatments, dose of BTZ, and comorbidities did not increase the severity of PN upon retreatment. The lapse of time between the two regimens also did not affect the severity of PN.


The results suggest that retreatment with BTZ may be a feasible option, without additional risks of PN, for MM patients even with peripheral neuropathy during their initial treatment with this drug.

Publisher URL: https://link.springer.com/article/10.1007/s00520-017-3732-6

DOI: 10.1007/s00520-017-3732-6

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.